James F Trotter
Affiliation: Baylor University Medical Center
- Renal dysfunction and the liver transplant recipient; novel strategies for determination of reversibility and renal protective therapies pretransplant and posttransplantJames Trotter
Baylor University Medical Center, Dallas, Texas, USA
Curr Opin Organ Transplant 17:225-9. 2012..Renal dysfunction is one of the most common and important complications in liver transplant candidates and recipients. Recent publications have highlighted important developments in this field...
- Hot-topic debate on hepatitis C virus: the type of immunosuppression mattersJames F Trotter
Baylor University Medical Center, Dallas, TX 75246, USA
Liver Transpl 17:S20-3. 2011..4. Because insulin resistance and diabetes are associated with fibrosis in HCV-infected liver transplant recipients, the use of immunosuppressive agents without this side effect may slow the posttransplant disease progression...
- Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort studyJames F Trotter
Department of Surgery, University of Colorado, Aurora, CO, USA
Liver Transpl 17:409-17. 2011..Persistently decreased platelet counts warrant further investigation...
- Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort studyJeffrey Campsen
Division of Transplant Surgery, University of Colorado, Aurora, CO 80262, USA
Liver Transpl 14:1273-80. 2008..Five of the 10 living donors had a total of 7 posttransplant complications. In conclusion, LDLT is rarely performed for ALF, but in selected patients it may be associated with acceptable recipient mortality and donor morbidity...
- Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complicationsJeffrey C Dunkelberg
Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
Liver Transpl 9:463-8. 2003..The prevalence of wound and hepatic artery complications is not different in liver transplant recipients administered sirolimus as part of a primary immunosuppressive regimen compared with historic controls...
- Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejectionMarcelo Kugelmas
Divisions of Gastroenterology Hepatology, University of Colorado, Denver, CO 80262, USA
Liver Transpl 9:1159-65. 2003..0006). In conclusion, IS levels decreased significantly in patients responding favorably to anti-HCV therapy. This decrease in IS levels may have a key role in predisposing these patients to ACR...
- Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantationPaul H Hayashi
Division of Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA
Am J Transplant 4:782-7. 2004..This balance is influenced greatly by the MELD system's determination of waiting times for HCC patients...
- Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELDPaul H Hayashi
Hepatology Section, University of Colorado Health Sciences Center, Denver, CO, USA
Liver Transpl 10:42-8. 2004..More stringent HCC diagnostic criteria will be required to decrease the effect that misdiagnosis has on organ allocation...
- Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantationRobert M Merion
Department of Surgery, University of Michigan, Ann Arbor, MI, USA
Ann Surg 251:542-9. 2010..To compare rates of hospitalization before and after adult-to-adult living donor liver transplant (LDLT) and deceased donor liver transplant (DDLT)...
- Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determinedJacqueline G O'Leary
Annette C and Harold C Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
Transpl Int 25:825-9. 2012..In conclusion, approximately half of HCV antibody-positive donors were aviremic. Viral dominance in viremic donor-recipient pairs seems virally determined...
- Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time courseJeffrey Campsen
Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO, USA
Liver Transpl 14:181-5. 2008..6-50.6 months). In conclusion, recurrent PSC following OLT is a formidable but protracted problem following OLT. Patients may require a second transplant following reemergent disease with reasonable survival benefit...
- Donor morbidity after living donation for liver transplantationRafik M Ghobrial
Department of Surgery, University of California Los Angeles, Los Angeles, California, USA
Gastroenterology 135:468-76. 2008..The rate and severity of complications in living donors were investigated in the 9-center Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)...
- Corticosteroid elimination in simultaneous liver-kidney transplantation recipientsNicholas K Weber
Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Aurora, CO, USA
Clin Transplant 23:958-63. 2009..While less common in kidney transplant alone recipients (KTA), corticosteroid discontinuation is performed routinely in liver transplantation, raising the question of optimal immunosuppression for SLK recipients...
- Outcomes of donor evaluation in adult-to-adult living donor liver transplantationJames F Trotter
Department of Surgery, University of Colorado, Denver, CO, USA
Hepatology 46:1476-84. 2007..CONCLUSION: Both donor and recipient features appear to affect acceptance for LDLT. These findings may aid the donor evaluation process and allow an objective assessment of the likelihood of donor candidate acceptance...
- Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantationJames F Trotter
Division of Gastroenterology Hepatology, University of Colorado, Denver, CO 80262, USA
Transplantation 75:473-6. 2003..In this study, we compare the comprehensive cost of LDLT with that of cadaveric-liver transplantation...
- Sirolimus and cardiovascular disease risk in liver transplantationGreg J McKenna
Department of Surgery, Baylor University Medical Center, Dallas, TX 75246, USA
Transplantation 95:215-21. 2013..There are no published reports of sirolimus CVD in liver transplantation...
- International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measureRuss Arjal
Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, B 154, Aurora, CO 80045, USA
Clin Liver Dis 13:67-71. 2009....
- Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantationJames F Trotter
Department of Surgery, University of Colorado, Denver, CO 80262, and Department of Transplant Services, Piedmont Hospital, Atlanta, GA, USA
Transplantation 83:1506-8. 2007....
- Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipientsJames F Trotter
Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
Liver Transpl 8:212-8. 2002....
- Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiologySrinath Chinnakotla
Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
Transplantation 92:341-5. 2011....
- Living donor liver transplantation and hepatitis CAaron C Baltz
University of Colorado, Health Sciences Center, Division of Gastroenterology/Hepatology, 4200 E. 9th Avenue, Rm B-154 Denver, CO 80262, USA
Clin Liver Dis 7:651-65, viii. 2003..The optimum clinical approach is to only consider living donor liver transplantation in HCV-infected recipients as a life-saving procedure and to attempt to eradicate HCV before transplantation to prevent recurrent infection...
- HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipientsNicholas K Weber
Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, Aurora, CO 80045, USA
Dig Dis Sci 55:505-9. 2010..Recurrence prophylaxis is typically long-term hepatitis B immune-globulin (HBIg) and an oral anti-HBV agent. Because of high HBIg costs and improving efficacy of new oral agents, there is increasing interest in HBIg discontinuation...
- Intensive care unit management of liver-related coagulation disordersKevin Dasher
Baylor University Medical Center, Dallas, TX 75246, USA
Crit Care Clin 28:389-98, vi. 2012..This article reviews the background of coagulopathy in patients with end-stage liver disease and management options and comments on common clinical scenarios...
- Practical management of acute liver failure in the Intensive Care UnitJames F Trotter
Transplantation, Baylor University Medical Center, Dallas, Texas 75246, USA
Curr Opin Crit Care 15:163-7. 2009..This review focuses on the practical aspects of the management of patients with acute liver failure in the ICU...